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Abstract
Background The combination of everolimus and the
imidazoquinoline derivative, BEZ235 (dactolisib), a dual
PI3K/mTOR inhibitor, demonstrated synergy in a preclinical
model.
Objective To establish clinical feasibility, a phase Ib dose-
escalation trial investigating safety and pharmacokinetics of
this combination in patients with advanced tumors was
performed.
Patients and Methods BEZ235 was orally administered daily
in escalating doses of 200, 400, and 800 mg along with evero-
limus at 2.5 mg daily in 28-day cycles. Nineteen patients were
enrolled. Adverse events and tumor responses were evaluated
using CTCAE v4.0 and RECIST 1.1, respectively.
Pharmacokinetic analyses were performed.
Results Common toxicities observed included fatigue, diar-
rhea, nausea, mucositis, and elevated liver enzymes. No con-
firmed responses were observed. BEZ235 pharmacokinetics
exhibited dose-proportional increases in Cmax and AUC0-24
over the three doses, with high inter-individual variability.
Non-compartmental and population pharmacokinetic-based
simulations indicated significant increases in everolimus
Cmax and AUC0-24 on day 28 and decreased clearance to
13.41 L/hr.
Conclusions The combination of BEZ235 and everolimus
demonstrated limited efficacy and tolerance. BEZ235 system-
ic exposure increased in a dose-proportional manner while
oral bioavailability was quite low, which may be related to
gastrointestinal-specific toxicity. The changes in steady-state
pharmacokinetics of everolimus with BEZ235 highlight po-
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BEZ235 in combination with everolimus demonstrated
superior survival in a preclinical model but limited
clinical efficacy.  
BEZ235 in combination with everolimus was poorly
tolerated at administered doses in this phase I study.
BEZ235 resulted in increases in everolimus steady 
state pharmacokinetics when administered together.
1 Introduction
The development of molecularly targeted agents (MTA),
small molecules or antibodies directed against specific onco-
genic targets has transformed cancer therapy, leading to im-
proved disease control and extended survival. However, only
a few MTAs, such as imatinib have been successful as single
agents, likely because many tumors develop alternate signal-
ing pathways or harbor additional genetic alterations, and,
hence, are not driven by a single mutation [1]. Therefore,
heterogeneous tumors presumably require inhibition of multi-
ple key signaling regulators, warranting combination therapy.
The phosphatidylinositol 3-kinase/AKT/mammalian target of
rapamycin (PI3K/AKT/mTOR) pathway has emerged as a
central pathway in cell survival, proliferation, and angiogene-
sis that is frequently dysregulated in cancer and its activation
has been associated with poor outcomes [2]. The mTOR in-
hibitor, everolimus (RAD001), is FDA-approved for the treat-
ment of renal cell carcinoma, subependymal giant cell astro-
cytoma, pancreatic neuroendocrine tumors, and advanced
breast cancer [3–5]. However, obtaining optimal clinical re-
sponses with single-agent everolimus is challenging, perhaps
due to loss of a negative feedback mechanism that results in
activation of PI3K and its downstream effectors, or due to
incomplete inhibition of mTORC1 substrates such as 4E-
BP1 [6, 7]. BEZ235 is a dual PI3K/mTOR inhibitor that binds
to the ATP-binding pocket of these enzymes, thereby
inhibiting PI3K along with mTOR complexes, TORC1, and
TORC2 [8]. Preclinical studies in mouse transgenic and xeno-
graft tumor models have shown that BEZ235 effectively in-
hibits growth of tumors, including glioblastoma, breast, lung,
pancreatic, and prostate cancer [9–12].
We previously reported that the combination of BEZ235
and everolimus slowed progression of hepatocellular
carcinoma (HCC) in mice [13]. Microarray gene expression
analyses revealed that a number of genes in tumors treated
with the drug combination, but not as single agents, reverted
to expression levels found in normal liver. Furthermore, the
expression of autophagy genes was decreased in tumors com-
pared to normal liver [13]. These findings formed the basis for
this phase I study to evaluate the safety and efficacy of this
combination in patients with advanced cancer.
Everolimus is primarily metabolized by CYP3A4 [14, 15]
and is also a substrate for efflux transporter P-glycoprotein (P-
gp) [16]. A number of clinical trials investigating drug–drug
interactions have established everolimus to be a sensitive
probe for alterations in CYP3A4/ P-gp activity [17].
Therefore, we chose a starting dose of 2.5 mg of everolimus
(rather than standard dosing of 10 mg) to account for this
interaction. We report a detailed description of the combina-




For this IRB-approved study, BEZ235 was supplied by
Novartis Oncology (East Hanover, NJ, USA). Patients
≥18 years with cytologically or histologically confirmed ad-
vanced or metastatic solid cancers that had exhausted standard
therapies were eligible for enrollment. At least one measurable
lesion defined by RECIST 1.1 was required [18]. Key inclu-
sion criteria were Eastern Cooperative Oncology Group per-
formance status (ECOG PS) ≤2, ability to understand and sign
informed consent, and adequate bone marrow and organ func-
tion [19]. Key exclusion criteria included prior anticancer ther-
apy within 4 weeks prior to enrollment, poorly controlled
diabetes, chronic immunosuppression, other serious disease
that may impact survival, abnormal gastrointestinal function
resulting in poor BEZ235 absorption, or required treatment
with other drugs that are known to modulate isoenzyme
CYP3A4.
2.2 Study Design and Dose Escalation Scheme
The study was an open-label, single-center, dose-escalation
trial assessing the safety and tolerability of the combination
of BEZ235 and everolimus (NCT01508104). The primary
objectives of the study were to determine the maximum toler-
ated dose (MTD) and dose-limiting toxicities (DLT) in pa-
tients with solid tumors. The secondary objective was to char-
acterize the PK of BEZ235 and everolimus in combination.
Nineteen patients were enrolled from 1/12/12 to 9/30/13
(Table 1). Patients were treated in 28-day cycles that included
once daily oral administration of everolimus and BEZ235.
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The starting dose of everolimus was 2.5 mg and 200 mg for
BEZ235. BEZ235 was escalated to 400 mg and 800 mg in
cohorts 2 and 3, respectively. Patients self-administered and
reported daily everolimus and BEZ235 dosing on a patient
calendar. Patients were treated until either unacceptable toxic-
ity was reached or until disease progression.
Safety was evaluated by monitoring adverse events, hema-
tology, blood chemistry profiles, and regular physical exams.
Adverse events were graded using CTCAE v4.1. Dose reduc-
tions and delays were allowed for significant drug-associated
toxicities of up to 2 weeks. At least three patients were en-
rolled in each cohort and dose escalation was permitted once
three patients were evaluable for DLT. At each given dose
level, there was a gap of 1 week between the inclusion of
the first patient and the next two patients. Assessment for
DLT was conducted during the first 28 days after enrollment.
The DLT was defined as febrile or grade 4 neutropenia
>7 days, grade 4 thrombocytopenia or grade 3 with bleeding,
grade 3 or 4 non-hematologic toxicity, treatment delay
≥2 weeks due to unresolved toxicity, or any other non-
hematologic toxicity grade 2 or higher that the investigator
and medical monitor felt was dose-limiting. If a patient devel-
oped a DLT, then three more patients were entered at that dose
level. The MTD was the dose in which ≤1 patient developed a
DLT.
2.3 Patient Evaluation
After informed consent, baseline visit included general de-
mography, medical history including medications, thorough
physical exam, vital signs, ECOG PS, ECG, blood collection
for standard laboratory investigation, cardiac and CT whole-
body imaging, brain MRI (for brain tumors), and pulmonary
function testing. Tumor response was measured using
























Male 3 3 6 12
Female 1 4 2 7
ECOG PS = 0 0 2 1 3
ECOG PS = 1 4 5 6 15
ECOG PS = 2 0 0 1 1
White 3 6 6 15
Black 1 1 1 3
Hispanic 0 0 1 1

















NSCLC 1 1 0 2
Brain tumor 1 1 1 3
Colon carcinoma 1 1 1 3
HCC 1 0 0 1
Pancreatic Ca 0 1 0 1
Esophageal Ca 0 1 1 2
Laryngeal ca
(adenoid cystic)
0 1 0 1
Appendix ca 0 1 0 1
HNSCC 0 0 1 1
Prostate ca 0 0 1 1
Ovarian ca 0 0 1 1
Rectal NET 0 0 1 1
Endometrial Ca 0 0 1 1
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RECISTcriteria every 8 weeks. After discontinuation of study
medication, an end of study visit was performed at 30 days.
2.4 Pharmacokinetic Assessment and Determination
of Everolimus and BEZ235 Concentrations
Blood samples for PK analysis of BEZ235 and everolimus
were obtained pre-dose and at 1, 2, 4, 6, 8, 10, and 24 h after
dosing on days 1 and 28. Additional blood samples were
collected at 48 and 72 h after the last dose (day 28). For
BEZ235 PK, blood was collected into sodium heparin tubes
and the plasma was separated. For everolimus PK, blood was
collected into ethylenediaminetetraacetic acid (EDTA)-con-
taining tubes and stored at -20 °C until analysis. Whole blood
was preferred for everolimus analysis as it is extensively dis-
tributed into erythrocytes with binding of 85%. BEZ235 con-
centrations were determined using fluorescence-based high-
performance liquid chromatography (HPLC) method using
BBD130 as an internal standard [20]. Everolimus concentra-
tions were measured using a validated liquid chromatography
coupled with mass spectrometer (LC-MS/MS) method
(Supplementary Methods).
2.5 Pharmacokinetic and Statistical Analysis
Non-compartmental analysis using Phoenix WinNonlin 6.3
(Pharsight, Mountain View, CA, USA) was performed to de-
termine PK parameters including area under the plasma
concentration-time curve from zero to last measurable time
point (AUC0-24), maximum plasma concentration (Cmax), time
to achieve the peak concentrations (Tmax), terminal elimina-
tion half-life (t1/2), and oral clearance (CL/F). The elimination
half-life (t1/2) was calculated as 0.693/λz, where λz is the
terminal-phase elimination rate constant. AUC0-24 was calcu-
lated using the linear trapezoidal rule area under the concen-
tration time curve from time zero to 24 hours. Dose propor-
tionality was assessed using the power model Y =α(dose)β,
where Y is the response variable (Cmax and AUC0-24), α is the
expected value of Yat a reference dose, and β is the exponent
used for examining the proportionality. In order to evaluate the
postulated impact of BEZ235 on everolimus PK, the single-
dose and steady-state systemic exposure of everolimus (Cmax
and AUC0-24) and CL/F derived from our study were com-
pared to those previously reported. Statistical analysis
(Wilcoxon signed rank test, at 0.05 significance) was per-
formed to test if there was a significant change in primary
PK parameters of everolimus from day 1 to day 28. We also
employed a population PK model using NONMEM 7.2 (Icon
Development Solutions, MD, USA) which facilitates non-




Thirty-four patients were screened and 19 patients were eligi-
ble for enrollment (Fig. 1). All had advanced solid tumors and
had failed conventional therapy (Table 1). About half of the
patients were male and the median age was 56 years (range,
36–73 years). The majority of patients had an ECOG PS of 1.
On average, patients had received at least three prior systemic
treatments.
3.2 Dose Escalation, Safety and Maximum Tolerated Dose
The study was initially designed to include five cohorts, but
due to early termination included only three (Supplementary
Table 1). The study was closed early due to exceeding the
MTD in cohort 3. All 19 patients reported at least one adverse
event. Four patients developed a DLT requiring discontinua-
tion of the study drug and one patient died. Several patients
reported malaise during the first several days of medication
and discontinued treatment despite symptom resolution but
did not fulfill criteria for DLT determination. Four additional
patients withdrew consent, one patient was removed for non-
compliance, and one had a prolonged delay in treatment due to
toxicity requiring discontinuation (Fig. 1). Overall, there were
196 adverse and 34 serious adverse events reported, of which
9 were unrelated to study medication (Table 2). The most
common adverse events included fatigue, anorexia, nausea,
diarrhea, and mucositis (Supplementary Table 2). On labora-
tory evaluation, elevated liver enzymes and anemia were the
most commonly recorded events.
In cohort 1, in which patients received 200 mg of BEZ235
and 2.5 mg everolimus, there were three serious adverse events,
but only one with elevation in liver enzymes was deemed to be
study drug-related. Non-related serious adverse events included
hydrocephalus in a patient with glioblastoma multiforme
(GBM) and pneumonia requiring hospitalization. Otherwise,
the first cohort of patients tolerated the treatment well and all
but one patient completed two full cycles. In cohort 2, the dose
of BEZ235 was escalated to 400 mg while everolimus dose
remained the same. A total of seven patients were treated in this
cohort as oneDLTwas observed. There were 14 serious adverse
events with the majority encompassing laboratory abnormali-
ties including elevated liver enzymes and anemia. The DLT
observed was due to angioedema and its relationship to the
study drug could not be excluded. In this cohort, several patients
developed nausea and diarrhea as well as mucositis. As muco-
sitis is a known side-effect of everolimus [21], the increased
rates of mucositis with two mTOR inhibitors was not unexpect-
ed. One case of diarrhea and one case of mucositis were related
to infectious causes: Clostridium difficile and herpes simplex
virus, respectively. Cohort 3 included 8 patients treated with
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BEZ235 at 800 mg with 2.5 mg everolimus. Most patients in
cohort 3 developed fatigue, mucositis, diarrhea and nausea and
several patients required treatment delays or dose reduction due
to drug toxicity with 17 serious adverse events. Of the grade 3/4
Table 2 Serious adverse events
(CTCAE grade 3–5) Toxicity category Toxicity Cohort 1 Cohort 2 Cohort 3
General symptoms Fatigue 1 (14) 1 (13)
Angioedema 1 (14)
Dehydration 2 (28)
Lab abnormalities ALT Elevation 1 (13)
AST Elevation 1 (25) 1+ (14) 2 (25)
Alkaline phosphatase elevation 2+ (28) 1 (13)
Elevated bilirubin 1+ (14)
Tumor lysis syndrome 1* (13)
Hypophosphatemia 1 (13)
Anemia 2 (28) 1 (13)
Neutropenia 1* (14)
Thrombocytopenia 1 (13)
Gastrointestinal symptoms Mucositis 1 (14) 1 (13)
Diarrhea 1 (14) 1 (13)
Nausea/vomiting 1 (13)
Hepatorenal syndrome 1* (13)
Infectious complications Gram positive bacteremia 2+** (25)
Pneumonia+ 1 (25)
Perforated diverticulitis+ 1* (13)
Neurologic symptoms Gait imbalance+ 1 (14)
Hydrocephalus+ 1* (25)
Peripheral neuropathy 1 (13)
+Due to disease progression rather than study medication. *Grade 4 events included neutropenia, tumor lysis
syndrome, hepatorenal syndrome, gram positive sepsis, diverticulitis, and hydrocephalus. **Grade 5 event in-
cluded an episode of gram positive sepsis. The percentage of adverse events in each cohort is indicated in ().




events, one patient developed diverticulitis and perforation
resulting in sepsis unrelated to treatment, while another devel-
oped tumor lysis syndrome (TLS) after only 5 days of treatment
with elevation in lactate dehydrogenase (LDH) and uric acid,
hepatorenal failure and gram-positive bacteremia which was
potentially related to treatment. The latter patient succumbed
to the adverse events and was recorded as a DLT. Two other
DLTs were observed: one due to a grade 3 peripheral neuropa-
thy, and on retrospective review of laboratory findings, it was
determined that a previous patient had experienced a DLT due
to grade 3 hypophosphatemia. Therefore, it was determined that
MTD had been reached in the previous cohort (400 mg of
BEZ235 and 2.5 mg of everolimus).
Only four patients (21%) completed two full cycles of treat-
ment and no patients began a third cycle, as all that were
evaluable at the end of cycle 2 had disease progression. The
most common reason for early termination was due to with-
drawal of consent, toxicity leading to prolonged delay, or a DLT.
3.3 Tumor Response
Eleven patients were evaluable for response. One patient with
astrocytoma had stable disease and no responses were observed
(Supplementary Table 3). Although treatment was tolerated
well in cohort 1, all patients in both cohort 1 and 2 developed
disease progression requiring study discontinuation. One pa-
tient with a rectal neuroendocrine tumor in cohort 3 had a tran-
sient clinical response at fifteen days; however, he developed
grade 3 laboratory abnormalities requiring treatment delay dur-
ing which he rapidly progressed and re-initiation of medication
was unsuccessful. Although, there was one confirmed stable
disease (SD) and one patient who had an observed initial clin-
ical response as described above, the study was discontinued
after cohort 3 due to intolerable adverse effects.
3.4 Pharmacokinetics of BEZ235
Plasma concentration-time profile data of BEZ235 at 200, 400,
and 800 mg on day 1 are shown in Fig. 2a, and the non-
compartmental PK parameters are listed in Table 3. The peak
plasma concentration of BEZ235 occurred approximately
3 hours after administration and the median Tmax values were
3.8 ± 1.6, 2.5 ± 0.9, and 2.6 ± 0.8 hours at doses of 200, 400,
and 800 mg, respectively. There was a significant inter-
individual variability in BEZ235 PK. The plasma concentration
maximum Cmax (mean ± SE) increased in a dose-proportional
manner from 45.2 ± 11.4, 101.8 ± 22.4 and 243.0 ± 52.7 ng/mL
and the corresponding dose normalized Cmax was 0.2, 0.3, and
0.3 at 200, 400, and 800 mg BEZ235 doses, respectively. The
AUC0-24 (mean ± SE) values were 433.4 ± 96, 741.3 ± 171.2,
and 2081.5 ± 666.2 hr*ng/mL for 200, 400, and 800 mg
BEZ235 doses, respectively. The elimination half-life showed
higher variability across dose groups with mean values of
3.2 hours at 200-mg, 8.6 hours at 400-mg, and 5.9 hours at
800-mg doses. Dose proportionality in BEZ235 PK was
established by linear regression analysis and also by a power
model for systemic exposure parameters Cmax and AUC0-24
with BEZ235 dose. The β-slope parameter for power model
for Cmax and AUC0-24 were 1.21 and 1.13, respectively.
Further, the linear regression of Cmax and AUC0-24 to
BEZ235 dose was linear with R2 of 0.9973 with P = 0.0127
(for slope ≠ 0) for Cmax and R2 of 0.9833 with P = 0.013 (for
slope ≠ 0) for AUC0-24 (Supplementary Figure 1). Steady-state
PK parameters of BEZ235 are listed in Table 3. There was a
significant accumulation of BEZ235 on day 28 as indicated by
Cmax and AUC0-24; steady-state terminal half-life was estimat-
ed to be 19.2 ± 2.5, 43.4 ± 10.8, and 15 ± 6.4 hours at doses of
200, 400, and 800 mg, respectively.
3.5 Everolimus Pharmacokinetics and Drug Interactions
Everolimus whole-blood concentration-time profile data at
2.5 mg/day is shown in Fig. 2b and PK parameters are listed
in Table 3. The Cmax on day 1 was 14.08 ± 1.5 ng/mL and was
observed at a Tmax of 4.3 ± 1.2 hours. The apparent clearance
(CL/F) was 24.76 ± 2.91 L/hr, which was close to the reported
everolimus clearance of 21.3 L/hr and 27.3 L/hr at 5 and
10 mg dosed alone [22]. To investigate any impact of
BEZ235 co-administration on everolimus PK, dose-
normalized AUC0-24 and Cmax observed on days 1 and 28
were compared with the reported values at 5 and 10 mg/day.
The AUC0-24 was 124.32 ± 12.7 ng*hr/mL on day 1 and in-
creased to 218.8 ± 33.26 ng*hr/mL on day 28. Similarly, Cmax
increased from 14.08 ± 1.5 ng/mL on day 1 to 31.68 ± 7.4 ng/
mL on day 28. In contrast, clearance of everolimus (CL/F)
decreased from 24.76 ± 2.91 L/h on day 1 to 13.41 ± 2.31 L/
hr on day 28. Dose-normalized exposure and clearance values
in this study were compared with everolimus PK from cancer
patients as reported in the Afinitor® clinical pharmacology
and biopharmaceutics review [23]. As shown in Fig. 3, there
was a significant increase in everolimus systemic exposure
(Cmax and AUC0-24) and corresponding decrease in everoli-
mus clearance (CL/F) on day 28. Dose-normalized Cmax of
everolimus was 9.29 ng/mL when given along with BEZ235
compared to 6.3 ng/mL when dosed alone. Similarly, there
was a 1.7-fold increase in dose-normalized AUC0-24 with the
combination of everolimus and BEZ235 when compared to
everolimus alone. Further, there was a statistically significant
decrease in clearance (P value = 0.0156) from day 1 to day 28.
Since there were only a few subjects in each BEZ235 dose
group, statistical analysis on the influence of BEZ235 dose on
everolimus exposure was not performed. Figure 3a shows
individual line plots of change in CL/F and AUC in different
subjects from day 1 to day 28, further illustrating the potential
drug–drug interaction, strongly suggesting a BEZ235 influ-
ence on everolimus PK.
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BEZ235 Dose Everolimus Dose
200 mg 400 mg 800 mg 2.5 mg
Day 1 Day 28 Day 1 Day 28 Day 1 Day 28 Day 1 Day 28
AUC 0-24
(ng*hr/mL)
433.4 ± 96 1474 ± 515.2 741.3 ± 171.2 1458.1 ± 1253.6 2081.5 ± 666.2 7795.1 ± 5608.7 124.32 ± 12.72 218.8 ± 33.26*
AUC 0-∞
(ng*hr/mL)
468.5 ± 118.2 1487.9 ± 690.9 830.8 ± 163.1 2707.6 ± 2343.3 2167.3 ± 674.9 8877 ± 6589.9 191.15 ± 33.72 693.76 ± 148.08
Cmax (ng/mL) 45.2 ± 11.4 214.4 ± 114.4 101.8 ± 22.4 227.3 ± 197.6 243 ± 52.7 880.3 ± 570.5 14.08 ± 1.5 31.68 ± 7.4
Cmax / Dose
(ng/mL/mg)
0.2 ± 0.1 1.1 ± 0.6 0.3 ± 0.1 0.6 ± 0.5 0.3 ± 0.1 1.1 ± 0.7 5.63 ± 0.6 12.67 ± 2.96












Fig. 2 Plasma concentration-
time profiles of BEZ235 and
everolimus. a) Plasma
concentration-time profile of
BEZ235 on day 1 after 200, 400,
and 800 mg/day dose. b) Plasma
concentration-time profile of
everolimus on day 1 and day 28
after 2.5 mg/day dose
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Additionally, we carried out population PK analysis of
everolimus blood levels in patients enrolled in this study and
compared the results to the reported population PK parameters
of everolimus [23]. A two-compartment model of disposition
fit the everolimus data well, and the final parameters including
the inter-individual variability are reported in the supplemen-
tary Table 4. We employed everolimus data from 18 subjects
who completed day 1 dosing (123 blood levels) and from 7
subjects who also completed the day 28 cycle (60 blood
levels). Based on the reported population PK parameters of
everolimus including fixed effects (structural model parame-
ters) and random effects (variance model parameters), evero-
limus concentrations were simulated for a once daily 2.5 mg
dose (Fig. 3b). There was no significant change in the evero-
limus exposure on day 1, as represented in Fig. 3, as most of
the observed everolimus concentrations fell within a 90% pre-
diction interval. However, almost all patients had everolimus
concentrations outside the 90% prediction interval on day 28,
indicating a significant change in the everolimus PK on day
28.
4 Discussion
This is the first report of clinical PKs of BEZ235 combined
with everolimus in patients with advanced solid tumors. Both
single-dose and steady-state PK of BEZ235 were evaluated
following 200, 400, and 800 mg administration once daily for
28 days. From preclinical studies, it is known that BEZ235
has low oral bioavailability with highly variable systemic ex-
posure due to poor aqueous solubility. Thus, we used a special
delivery system (SDS) in the form of a sachet in an attempt to
overcome poor solubility and to reduce the inter-individual
variability in PK. Despite these efforts, our data suggest that
the oral availability of BEZ235 remained low. Recently,
Bendell et al. reported a similar highly variable PK of
BEZ235 in a phase I study at doses 300–600 mg given twice
daily using a similar SDS sachets [24].
The PK studies were focused primarily on assessing three
important issues. Firstly, we explored the relationship between
systemic exposure and the administered oral dose of BEZ235.
Despite the inter-subject variability that is typically seen in
advanced cancer patients, the Cmax and AUC0-24 increased
in a linear (dose-proportional) manner following single dose
administration. The power model also underscored this trend;
although, with a slope factor of 1.21 for Cmax and 1.13 for
AUC0-24, the increase may be supra-proportional. A limitation
of the power model was that this phase I study was not pri-
marily powered to detect any non-linearity in PK. Secondly,
we evaluated the steady-state PK of BEZ235 to capture daily
fluctuations in drug levels and the extent of drug accumulation
upon multiple dosing. Steady-state PK, assessed on day 28 of
the study could only be evaluated in a few subjects, which was
difficult to analyze given dose proportionality and inter-
Fig. 3 PK analysis for
everolimus. a) Individual change
in everolimus AUC0-24 and CL/F
from day 1 to day 28. b)
Simulated concentration-time
profile of everolimus at 2.5 mg/
day using the reported population
pharmacokinetic model (mean
concentrations: black; 90% con-
fidence interval: grey shaded ar-
ea) and observed concentrations
from the current study (mean:
circles; 90% confidence interval:
black line)
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subject variability. The average plasma concentration of
BEZ235 ranged from 61–324 ng/ml at doses of 200 to
800 mg/day. Accumulation was 2–3-fold higher than antici-
pated given the steady-state half-life of BEZ235, which
ranged from 15–43 hrs. Exposure to a once daily dose of
BEZ235 was comparable to twice-daily dosing reported by
Bendell et al. [24]; AUC0-24 at 400 mg once daily
(741.3 ng*hr/mL) was close to 200 mg twice daily
(752.9 ng*hr/mL). Thirdly, we assessed if there was a PK
interaction between BEZ235 and everolimus. The PK of
everolimus has been well-characterized in healthy subjects
and patients with advanced solid tumors with a linear PK
observed at up to 10-mg/day doses. While rapidly absorbed
after oral administration with a median Tmax of 1–2 hours, oral
bioavailability of everolimus is low. This is believed to be due
to extensive intestinal and first pass hepatic clearance mediat-
ed primarily by CYP3A4 metabolism and efflux by P-gp.
Everolimus has a narrow therapeutic index and its FDA label
recommends drug monitoring for everolimus when co-
administered with CYP3A4 and/or P-gp inducers or inhibitors
based on prior studies [16, 17]. In an earlier study employing a
human liver microsomal system, we observed that BEZ235 is
a time-dependent CYP3A4 inhibitor. Thus, we assessed the
impact of BEZ235 on everolimus PK on day 1 and day 28
comparing our data to previous reports [23]. We employed
both a non-compartmental and population-based PK analyses
[25]. Results indicate that there was a significant change in
everolimus PK due to BEZ235 co-administration. In all sub-
jects, there was a significant decrease in everolimus clearance
on day 28 from day 1 and clearance was lower than the re-
ported clearance of everolimus monotherapy. Everolimus ex-
posure when dosed along with BEZ235 was 1.7-fold higher
and the resulting mean everolimus exposure at 2.5 mg/day
was approximately equivalent to everolimus 5-mg/day mono-
therapy. Using a population-based PK model, we showed that
the observed everolimus concentrations on day 1 were consis-
tent with the previously reported everolimus PK; however,
there was a significant increase in exposure on day 28.
Time-dependent inhibition of CYP3A4 by BEZ235 could po-
tentially rationalize this increase in everolimus exposure.
Most adverse events observed were consistent with the
reported profile of mTOR inhibitors including fatigue, muco-
sitis, diarrhea, nausea, and myelosuppression, or PI3K inhib-
itors including elevated liver enzymes [4, 5, 24]. Potentially,
the low oral bioavailability of BEZ235 resulted in high GI
concentrations contributing to the GI-specific toxicities re-
ported. However, unanticipated toxicities were also observed,
including the development of TLS. It is unclear whether this
was directly related to the studymedication, but may implicate
increased response in this patient. Unfortunately, the patient
who developed TLS on treatment succumbed to complica-
tions of TLS. It should be cautionary to consider allopurinol
TLS prophylaxis in patients with aggressive, highly
proliferative tumors and a high volume of disease who will
receive mTOR/PI3K inhibitors. Tapering of steroids was re-
quired in our study and we observed that patients with GBM
often developed rapid deterioration that prohibited patient
continuation on study. Therefore, patients requiring steroids
may not be ideal candidates for this treatment.
Although this study was not designed to capture efficacy,
and preclinical studies demonstrated the synergy of combin-
ing an mTOR inhibitor and a dual mTOR/PI3K inhibitor
(BEZ235), we did not observe any RECIST-defined responses
in this phase 1 trial. There was one patient who had SD and
one who had a brief clinical response in cohort 3. However,
due to subjective and objective unacceptable toxicity, patients
were unable to complete two cycles of treatment at the esca-
lated dose of BEZ235. Moreover, pharmacodynamics (PD)
analyses using patient-derived mononuclear cells from day 1
(pre-treatment) and 28 (post-treatment) in six patients showed
a trend towards decreased phosphorylation of 4E-BP1, a
downstream substrate of mTOR (data not shown). However,
the inter-patient variability and the low number of patients per
treatment cycle preclude any conclusive statement regarding
PD. Altogether, the poor bioavailability of BEZ235 combined
with the reported toxicities prevented dose escalation to where
efficacy could potentially be achieved. Thus, to avoid these
toxicities and achieve a dose likely to be impact the PI3K/
mTOR pathway, a formulation that markedly enhances the
oral bioavailability or delivery of the drug via a non-oral route
must be considered.
Importantly, it should be noted that development of
dactolisib has been halted. Other clinical studies in several
tumors including a phase I trial of BEZ235 alone in pancreatic
neuroendocrine tumors [26] and a combination study with
mTOR inhibition in bladder cancer [27] also showed that
BEZ235 was poorly tolerated as the MTD was 300 mg in
the phase I study [24]. These studies did demonstrate limited
clinical efficacy with several patients with stable disease but
given the poor tolerability, these trials did not advance.
Our studies provide the first detailed report on the PK of
BEZ235 in combination with everolimus and suggest that the
systemic exposure of BEZ235 likely exhibits a linear/dose-
proportional pattern in the range of 200–800 mg. At steady
state, drug levels are ∼3-fold higher than following single dose
administration. The compound is likely to cause changes in
the PK of drugs where CYP3A4 plays a prominent role, as
was observed with everolimus. Most likely this interaction
occurs in the gastrointestinal (GI) tract since everolimus is
known to undergo extensive pre-systemic clearance and the
intestinal concentrations of BEZ235 are likely to be higher
given its low oral bioavailability. Thus, this interaction may
not make a major impact on drugs that are not metabolized in
the GI tract. The results of our studies strongly underscore the
critical need for consideration of biopharmaceutical properties
in designing investigational agents targeting mTOR/PI3K
Targ Oncol
signaling and drug delivery approaches, in order to achieve
therapeutically relevant systemic drug exposure.
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